Estuardo Aguilar-Cordova - 29 Jul 2021 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Role
Chief Scientific Officer, Director
Signature
/s/ John Canepa, Attorney-in-Fact
Issuer symbol
CADL
Transactions as of
29 Jul 2021
Net transactions value
$0
Form type
4
Filing time
02 Aug 2021, 20:12:06 UTC
Previous filing
26 Jul 2021
Next filing
10 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CADL Common Stock Conversion of derivative security +162,137 +19% 1,015,923 29 Jul 2021 Direct F1, F2
holding CADL Common Stock 2,074,942 29 Jul 2021 By Estuardo Aguilar-Cordova 2020 Irrevocable Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CADL Series B Preferred Stock Conversion of derivative security $0 -398,519 -100% $0.000000* 0 29 Jul 2021 Common Stock 162,137 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date.
F2 Includes 32,399 shares of common stock held jointly with spouse.
F3 Shares held by the Estuardo Aguilar-Cordova 2020 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.

Remarks:

Exhibit 24 - Power of Attorney